112 related articles for article (PubMed ID: 11086167)
1. Thyroglobulin type-I-like domains in invariant chain fusion proteins mediate resistance to cathepsin L digestion.
Hitzel C; Kanzler H; König A; Kummer MP; Brix K; Herzog V; Koch N
FEBS Lett; 2000 Nov; 485(1):67-70. PubMed ID: 11086167
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.
Guncar G; Pungercic G; Klemencic I; Turk V; Turk D
EMBO J; 1999 Feb; 18(4):793-803. PubMed ID: 10022822
[TBL] [Abstract][Full Text] [Related]
3. The p41 fragment story.
Turk D; Guncar G; Turk V
IUBMB Life; 1999 Jul; 48(1):7-12. PubMed ID: 10791909
[TBL] [Abstract][Full Text] [Related]
4. Both invariant chain isoforms Ii31 and Ii41 promote class II antigen presentation.
Serwe M; Reuter G; Sponaas A; Koch S; Koch N
Int Immunol; 1997 Jul; 9(7):983-91. PubMed ID: 9237107
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation.
Mihelic M; Dobersek A; Guncar G; Turk D
J Biol Chem; 2008 May; 283(21):14453-60. PubMed ID: 18362148
[TBL] [Abstract][Full Text] [Related]
6. Equistatin, a new inhibitor of cysteine proteinases from Actinia equina, is structurally related to thyroglobulin type-1 domain.
Lenarcic B; Ritonja A; Strukelj B; Turk B; Turk V
J Biol Chem; 1997 May; 272(21):13899-903. PubMed ID: 9153250
[TBL] [Abstract][Full Text] [Related]
7. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain.
Fineschi B; Sakaguchi K; Appella E; Miller J
J Immunol; 1996 Oct; 157(8):3211-5. PubMed ID: 8871612
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis.
Tolosa E; Li W; Yasuda Y; Wienhold W; Denzin LK; Lautwein A; Driessen C; Schnorrer P; Weber E; Stevanovic S; Kurek R; Melms A; Bromme D
J Clin Invest; 2003 Aug; 112(4):517-26. PubMed ID: 12925692
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin S, but not cathepsin L, participates in the MHC class II-associated invariant chain processing in large yellow croaker (Larimichthys crocea).
Li Q; Ao J; Mu Y; Yang Z; Li T; Zhang X; Chen X
Fish Shellfish Immunol; 2015 Dec; 47(2):743-50. PubMed ID: 26475363
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands.
Honey K; Nakagawa T; Peters C; Rudensky A
J Exp Med; 2002 May; 195(10):1349-58. PubMed ID: 12021314
[TBL] [Abstract][Full Text] [Related]
11. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
Bevec T; Stoka V; Pungercic G; Dolenc I; Turk V
J Exp Med; 1996 Apr; 183(4):1331-8. PubMed ID: 8666891
[TBL] [Abstract][Full Text] [Related]
12. The p41 isoform of invariant chain is a chaperone for cathepsin L.
Lennon-Duménil AM; Roberts RA; Valentijn K; Driessen C; Overkleeft HS; Erickson A; Peters PJ; Bikoff E; Ploegh HL; Wolf Bryant P
EMBO J; 2001 Aug; 20(15):4055-64. PubMed ID: 11483509
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and NMR structure of p41icf, a potent inhibitor of human cathepsin L.
Chiva C; Barthe P; Codina A; Gairí M; Molina F; Granier C; Pugnière M; Inui T; Nishio H; Nishiuchi Y; Kimura T; Sakakibara S; Albericio F; Giralt E
J Am Chem Soc; 2003 Feb; 125(6):1508-17. PubMed ID: 12568610
[TBL] [Abstract][Full Text] [Related]
14. Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue.
Zavasnik-Bergant V; Sekirnik A; Golouh R; Turk V; Kos J
Biol Chem; 2001 May; 382(5):799-804. PubMed ID: 11517933
[TBL] [Abstract][Full Text] [Related]
15. Improvement of cathepsin S detection using a designed FRET peptide based on putative natural substrates.
Oliveira M; Torquato RJ; Alves MF; Juliano MA; Brömme D; Barros NM; Carmona AK
Peptides; 2010 Apr; 31(4):562-7. PubMed ID: 20045715
[TBL] [Abstract][Full Text] [Related]
16. Primary structure of the gene for the murine Ia antigen-associated invariant chains (Ii). An alternatively spliced exon encodes a cysteine-rich domain highly homologous to a repetitive sequence of thyroglobulin.
Koch N; Lauer W; Habicht J; Dobberstein B
EMBO J; 1987 Jun; 6(6):1677-83. PubMed ID: 3038530
[TBL] [Abstract][Full Text] [Related]
17. Proteases, processing, and thymic selection.
Cresswell P
Science; 1998 Apr; 280(5362):394-5. PubMed ID: 9575085
[No Abstract] [Full Text] [Related]
18. Potential sites for processing of the human invariant chain by cathepsins D and E.
Kageyama T; Yonezawa S; Ichinose M; Miki K; Moriyama A
Biochem Biophys Res Commun; 1996 Jun; 223(3):549-53. PubMed ID: 8687433
[TBL] [Abstract][Full Text] [Related]
19. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
[TBL] [Abstract][Full Text] [Related]
20. Lysosomal cysteine proteases and antigen presentation.
Rudensky A; Beers C
Ernst Schering Res Found Workshop; 2006; (56):81-95. PubMed ID: 16329647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
